Learning to Live With Missing Quality-of-Life Data in Advanced-Stage Disease Trials

Donaldson, Gary; Moinpour, Carol M.

doi:10.1200/jco.2005.07.022

Cited by 50 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer patients may have a number of physical symptoms, which affect quality of life, thus making it more challenging to recognise depression [4,6,7,12,14]. Many factors are closely related to depression in cancer patients, however little is known about the contributory factors in lung cancer [7,10,14,21,36] Hopwood et al found that functional impairment was the most important risk factor for depression [13].…”

Section: Introductionmentioning

confidence: 97%

Screening for depressive symptoms in patients with unresectable lung cancer

Néron

Correa

Dajczman

et al. 2007

Support Care Cancer

View full text Add to dashboard Cite

Forty-nine patients, aged 38-82 years (median age 63 years) were enrolled. All patients had advanced NSCLC (stages 3A, 3B and 4) and 61% (30 patients) had an ECOG performance status (PS) of 1 or greater. The point prevalence of depression measured by an interviewer using the MADRS at visits 1-4 was 49%, 51%, 47%, and 41%, respectively. The point prevalence of self-reported depression (HADS) was significantly (p < 0.001) lower at each assessment point (18%, 20%, 6%, 12%) compared to health professional detected depression (MADRS). Although MADRS and HADS showed very strong (Pearson's correlation = 0.8) and significant (p < 0.001) correlation, the concordance rate in identifying the same cases of depression was only 54%. CLINICAL IMPLICATION AND CONCLUSION: The prevalence of depression among advanced lung cancer patients is high and varies very little during the first 2 cycles of chemotherapy. Among a variety of tools available for the screening of depression, a semi-structured interview is more effective at identifying clinically significant depression than a self-administered questionnaire.

show abstract

Section: Introductionmentioning

confidence: 97%

Screening for depressive symptoms in patients with unresectable lung cancer

Néron

Correa

Dajczman

et al. 2007

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Incomplete data are of particular importance in QoL questionnaires, whether generic or specific, where items are aggregated to compute total (sub)scale scores: any missing item in a subscale will cause the whole scale score to be missing. As in other research fields, determining the type of missingness (as defined by Little and Rubin [7] who distinguished the processes of missing completely at random, missing at random and missing not at random) is often considered as the first step in the identification of the most appropriate method for analysis of the data [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Missing data methods for dealing with missing items in quality of life questionnaires. A comparison by simulation of personal mean score, full information maximum likelihood, multiple imputation, and hot deck techniques applied to the SF-36 in the French 2003 decennial health survey

2010

View full text Add to dashboard Cite

show abstract

“…Here, we used TTD in QoL as a conservative approach that took into account nonignorable missing data in cancer clinical trials [18]. Indeed, as can be expected in cancer clinical trials, a substantial proportion of patients often progress or deteriorate and withdraw from the study.…”

mentioning

confidence: 99%

Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer

et al. 2011

View full text Add to dashboard Cite

Purpose. This prospective multicenter study explored different definitions of time to deterioration (TTD) in quality of life (QoL) scores, according to different cutoffs of the minimal clinically important difference (MCID) as a modality for longitudinal QoL assessment in breast cancer patients.Methods. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and BR-23 before surgery, after surgery, and 6 and 12 months later. The global health score, arm symptoms score (BRAS), and breast symptoms score were analyzed. For a given baseline score, QoL was considered to have deteriorated if this score decreased by >5 points at any time point after baseline. Analyses were repeated using an MCID of 10 points and taking the score after surgery as the reference score (to explore the occurrence of response shift). TTD was calculated using the Kaplan-Meier method and Cox regression was used to identify independent factors associated with TTD.Results. Two hundred thirty-five patients underwent axillary lymph node dissection (ALND), 222 underwent sentinel lymph node biopsy (SLNB), and 61 underwent SLNB plus ALND. Patients who underwent SLNB had a significantly longer TTD for the BRAS dimension than those who underwent ALND. Cox multivariate analyses showed that treatment using SLNB and age >59 years were independently associated with longer TTD for the

show abstract

Learning to Live With Missing Quality-of-Life Data in Advanced-Stage Disease Trials

Cited by 50 publications

References 18 publications

Screening for depressive symptoms in patients with unresectable lung cancer

Screening for depressive symptoms in patients with unresectable lung cancer

Missing data methods for dealing with missing items in quality of life questionnaires. A comparison by simulation of personal mean score, full information maximum likelihood, multiple imputation, and hot deck techniques applied to the SF-36 in the French 2003 decennial health survey

Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer

Contact Info

Product

Resources

About